Cholestech System Benefits Stanford University School of Medicine Study
26 Februar 2007 - 3:18PM
PR Newswire (US)
Alternate Site Testing an Asset to Study and Patient Care HAYWARD,
Calif., Feb. 26 /PRNewswire-FirstCall/ -- The Stanford Prevention
Research Center of the Stanford University School of Medicine and
the San Mateo Medical Center in San Mateo, CA, have confirmed the
benefits of alternate site cholesterol and glucose screening,
counseling and patient health care management in improving the
treatment and prognosis of cardiac patients. The findings are an
outcome of the first phase of a four-year study utilizing the
Cholestech LDX(R) and GDX(TM) testing systems from Cholestech
Corporation (NASDAQ:CTEC), the nation's leading provider of
alternate site health management solutions for chronic disease.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042 ) The
"Heart to Heart" study is a randomized clinical trial to test the
impact of typical primary care versus case-management care
consisting of individualized treatment and counseling for cardiac
patients. Approximately 400 high-risk cardiac patients without
private health insurance and consisting of a mix of ethnicities
were divided into two equal groups. All patients were initially
screened with the Cholestech LDX and GDX alternate site testing
systems at baseline and at 15 months, which is the completion of
the first phase of the study. The case management patients received
approximately three additional Cholestech LDX screenings during
that time frame. The Cholestech LDX and GDX instruments screen for
lipids and glucose, using blood samples obtained with simple
fingersticks. Certified lab-accurate results are produced within
minutes. Control group members received their usual primary care
and no supplemental counseling. The case management group received
typical primary care in addition to one-on-one counseling with
nurses and dieticians that consisted of goal-setting for risk
reduction, lifestyle and medication adherence, and medication
management. Case manager contact for each patient during the first
15 months of the study totaled 14 hours. Said Linda Kleiman, ANP
and lead case manager for the Heart to Heart Study, "The Cholestech
LDX and GDX systems proved to be invaluable tools for our
clinicians during the course of the project. These systems are easy
to use and provide lab-accurate results within minutes. The results
can be reviewed with patients during office visits and changes in
medical management can be easily made on the spot, without having
to wait for lab samples to be drawn and processed. In addition, the
machines are incredibly durable and reliable and are easily
transported. We had a highly positive experience using these two
alternate site testing systems during the Heart to Heart project."
At 15 months, the case management group was moved into a
maintenance program and the control group was moved into case
management care. At that time, the LDL (low-density lipoprotein)
for case management patients fell an average of 10.2 points and
triglycerides fell 5.5 points. The average systolic blood pressure
fell from 132 to 127 and the average risk of heart attack dropped
from 17.6 to 16.7, as measured by the Framingham Risk computation
system. No significant changes in body mass index and A1C were
reported. "These studies are important because their results
support the value of alternate site testing in improving patient
compliance and, ultimately, overall health," said Warren E.
Pinckert II, President and CEO of Cholestech. Practitioners also
benefit as well from the LDX and GDX systems. "In addition to
providing patients with immediate and individualized counseling,
the instruments allow health care providers to eliminate the
outsourcing of blood samples to external labs, increasing
efficiency and lowering overhead costs." About Cholestech LDX and
GDX The Cholestech LDX System provides a complete lipid profile
with lab-accurate results in less than five minutes. The LDX is
CLIA-waived and certified to the Cholesterol Reference Method
Laboratory Network (CRMLN) standard established by the Centers for
Disease Control and Prevention (CDC) for total and HDL cholesterol.
The LDX provides a complete lipid profile that includes total
cholesterol, HDL, triglycerides, LDL, non-HDL, total
cholesterol/HDL ratio; glucose; Alt-AST liver enzymes; and hs-CRP,
high sensitivity C-reactive protein. The Cholestech GDX System
measures the average blood glucose level by reading the
concentration of A1C within red blood cells. A1C levels are
important in diabetes management as they indicate blood sugar
control over a period of two to three months, which is the
approximate life span of red blood cells. (A1C is also known as
glycohemoglobin, glycated hemoglobin or glycosylated hemoglobin.)
Since A1C levels are not subject to the fluctuations that are seen
in daily blood glucose monitoring, the American Diabetes
Association recommends A1C as the best test to determine if a
patient's blood sugar is under control over time. The GDX provides
laboratory-accurate, National Glycohemoglobin Standardization
Program (NGSP)-certified quantitative A1C results. About Cholestech
Cholestech is committed to enabling people to lead longer,
healthier and more active lives. Cholestech provides easy to use,
accessible diagnostic tools and information to health care
practitioners in over 35 countries around the world. Cholestech
offers efficient and economic diagnostic testing for cholesterol
and related lipids, blood glucose and glycemic control, and liver
enzymes at the point of care. Health care providers can use the
CLIA-waived Cholestech LDX(R) and GDX(TM)* Systems and the hs-CRP
test, which is cleared by the FDA for use in moderate complexity
labs, to initiate and monitor the progress of patient therapy. By
providing effective disease management solutions, Cholestech's goal
is to be a leading provider of diagnostic tools and information for
immediate risk assessment and therapeutic monitoring of heart
disease, inflammatory disorders and diabetes. *The GDX system is
510(k) cleared for prescription home use and, accordingly, is CLIA
waived. Cholestech LDX is a registered trademark and Cholestech GDX
is a trademark of Cholestech Corporation. All other trademarks
mentioned in this document are the property of their respective
owners. For more information about Cholestech and its products
visit us on the Web at http://www.cholestech.com/ . CTEC-G Contact:
Heather Battaglia HLD/Blankman Public Relations 516-536-6811 SOURCE
Cholestech Corporation
http://www.newscom.com/cgi-bin/prnh/20060504/NYTH042
http://photoarchive.ap.org/ CONTACT: Heather Battaglia of
HLD/Blankman Public Relations, +1-516-536-6811, or , for Cholestech
Web site: http://www.cholestech.com/
Copyright
Global X CleanTech ETF (NASDAQ:CTEC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Global X CleanTech ETF (NASDAQ:CTEC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Global X CleanTech ETF (NASDAQ): 0 Nachrichtenartikel
Weitere Cholestech (MM) News-Artikel